Insider Transactions in Q4 2020 at Codiak Bio Sciences, Inc. (CDAK)
Insider Transaction List (Q4 2020)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 16
2020
|
Alaska Permanent Fund Corp |
BUY
Open market or private purchase
|
Indirect |
235,000
+4.95%
|
$3,525,000
$15.0 P/Share
|
|
Oct 16
2020
|
Alaska Permanent Fund Corp |
BUY
Conversion of derivative security
|
Indirect |
4,213,932
+13.69%
|
-
|
|
Oct 16
2020
|
Steven Gillis Director |
BUY
Open market or private purchase
|
Indirect |
235,000
+8.58%
|
$3,525,000
$15.0 P/Share
|
|
Oct 16
2020
|
Steven Gillis Director |
BUY
Conversion of derivative security
|
Indirect |
2,204,940
+32.38%
|
-
|
|
Oct 16
2020
|
Douglas E Williams President & CEO |
BUY
Conversion of derivative security
|
Direct |
9,585
+50.0%
|
-
|
|
Oct 16
2020
|
Arch Venture Fund Viii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
235,000
+8.58%
|
$3,525,000
$15.0 P/Share
|
|
Oct 16
2020
|
Arch Venture Fund Viii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,555,135
+29.84%
|
-
|
|
Oct 16
2020
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
165,000
+12.61%
|
$2,475,000
$15.0 P/Share
|
|
Oct 16
2020
|
Flagship Ventures Fund V General Partner LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,956,354
+28.89%
|
-
|
|
Oct 13
2020
|
Kyriazi Theo Melas Director |
BUY
Open market or private purchase
|
Direct |
6,600
+50.0%
|
$99,000
$15.0 P/Share
|